font size

Gastrointestinal Diseases at a Glance (cont.)

Impact of the IBD as a Chronic Disease

IBD is one of the five most prevalent gastrointestinal disease burdens in the United States, with an overall health care cost of more than 1.7 billion. This chronic condition is without a medical cure and commonly requires a lifetime of care. Each year in the United States, IBD accounts for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients. Over the long term, up to 75% of patients with Crohn's disease and 25% of those with ulcerative colitis will require surgery.

Current CDC IBD Activities

CDC uses collaborations and resources to help better define and understand IBD.

  • CDC scientists and epidemiologists provide technical expertise to extramural researchers and fund pilot projects to describe the epidemiology and causes of IBD, including both Crohn's disease and ulcerative colitis.
  • CDC, in collaboration with a nationwide geographically diverse network of large managed health care delivery systems, supports an epidemiological study of IBD to understand IBD incidence, prevalence, demographics and healthcare use. The Crohn's and Colitis Foundation of America implemented the extramural activities of this 3-year epidemiology collaboration. This study found an average annual incidence rate of 8.4 per 100,000 people for Crohn's disease and 12.4 per 100,000 for ulcerative colitis (unpublished data).
  • During the initial 3-year epidemiologic collaboration, CDC laboratory workers and epidemiologists worked to improve detection tools and epidemiologic methods to study the role of infections (infectious disease epidemiology) in pediatric IBD, collaborating with extramural researchers who were funded by an NIH R03 research award. A senior CDC medical epidemiologist also served as adviser on other epidemiologic and causation studies conducted by the multi-region consortium of pediatric IBD gastroenterologists
  • In FY 2006 and FY2007, CDC epidemiologists are working in conjunction with the Crohn's and Colitis Foundation and a large health maintenance organization to better understand the natural history of IBD and factors that predict the course of disease. The current study will address questions regarding practice variation such as variability in quality of treatment given to patients with IBD in the community setting; patient, provider, or clinic predictors of treatment variability; and possible effects of this variability, if any, on patient outcomes.

SOURCES:

CDC

Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastro May 2004;126(6):1504–1517.

PL Lakatos. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 2006 October 14;12(38): 6102–6108.

S Hanauer. Inflammatory Bowel Disease: Epidemiology, pathogenesis and therapeutic opportunities. Inflamm Bowel Dis Jan 2006;12, Suppl 1.

Sleisenger & Fordtran's gastrointestinal and liver disease : pathophysiology, diagnosis, management / [edited by] Mark Feldman, Lawrence S. Friedman, Lawrence J. Brandt.—8th ed. Publisher Saunders an imprint of Elsevier, Philadelphia, PA . Printed in Canada 2006.


Last Editorial Review: 4/30/2010 3:15:20 PM



Women's Health

Find out what women really need.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations